Egret Therapeutics, a portfolio company of Turret Capital Management, is a clinical stage biotechnology company focused on function preservation following acute injury
Egret Therapeutics, Inc. (“Egret”), a clinical-stage biotechnology company developing novel immune-modulatory therapies for secondary inflammation following traumatic and ischemic disorders, today announced the signing of a non-binding Memorandum of Understanding (MOU) with Genexine, Inc. (KOSDAQ: 095700) to acquire full right, title, and interest in its lead asset, GX-P1 (also known as EGT-101).
“Securing full ownership of EGT-101 is a defining moment for Egret,” said Daniel Chai, MD, Co-Founder and CEO of Egret Therapeutics. “By consolidating the intellectual property for this first-in-class PD-1 agonist, we gain the strategic autonomy needed to accelerate development and maximize the potential of our platform to deliver life-changing therapies to patients suffering from acute secondary inflammation.”
Under the terms of the MOU, signed March 6, 2026, the parties intend to transition Egret’s current exclusive global license into an outright asset transfer. Subject to the execution of a definitive agreement, the proposed transaction would grant Egret sole ownership of the licensed product and all related intellectual property and materials.
“This MOU represents a transformative milestone for Egret,” said Henry Park, Chief Financial Officer of Egret Therapeutics. “Transitioning from licensee to outright owner of EGT-101 significantly strengthens our strategic position, simplifies our intellectual property structure, and provides the flexibility to pursue strategic partnerships and long-term value creation opportunities.”
Vedik Navale, Chief of Staff at Egret Therapeutics, added: “Our preclinical data show that PD-L1 dramatically reduces Malignant Cerebral Edema to preserve neurological function and improve survival. We are focused on executing our Phase 1b/2a study in Malignant Cerebral Edema following Large Vessel Occlusion Stroke with the urgency these patients need.”
